PUT/VERTEX PHARMACEUTICALS/500/0.1/16.01.26

PUT/VERTEX PHARMACEUTICALS/500/0.1/16.01.26 Share Price

DE000GG24AA9

Real-time BOERSE MUENCHEN 07:56:28 03/07/2024 pm IST
6.26 ^EUR	-0.95%

Current month	-1.10%
1 month	-14.48%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart VERTEX PHARMACEUTICALS INCORPORATED

Chart PUT/VERTEX PHARMACEUTICALS/500/0.1/16.01.26

Latest news about VERTEX PHARMACEUTICALS INCORPORATED

FDA Accepts Vertex Pharmaceuticals' New-Drug Application for Combination Therapy to Treat Cystic Fibrosis	02/07	MT
Vertex Gets Speedy FDA Review of Vanza Triple Cystic Fibrosis Therapy	02/07	DJ
Vertex Announces FDA Acceptance of New Drug Application for Vanzacaftor/Tezacaftor/Deutivacaftor, a Next-In-Class Triple Combination Treatment for Cystic Fibrosis	02/07	BU
Vertex Pharmaceuticals Incorporated Announces FDA Acceptance of New Drug Application for Vanzacaftor/Tezacaftor/Deutivacaftor, A Next-In-Class Triple Combination Treatment for Cystic Fibrosis	02/07	CI

More news

Quotes 5-day view

Date	Price	Change
03/24/03	6.26	-0.95%
02/24/02	6.32	-0.94%
01/24/01	6.38	-0.16%
28/24/28	6.39	+1.11%
27/24/27	6.32	-0.94%

Real-time BOERSE MUENCHEN

Last update July 03, 2024 at 07:56 pm IST

More quotes

Static data

Product type	Warrants
Buy / Sell	PUT
Underlying	VERTEX PHARMACEUTICALS INCORPORATED
Issuer	Goldman Sachs
WKN	GG24AA
ISIN	DE000GG24AA9
Date issued	23/01/2024
Strike	500 $
Maturity	16/01/2026 (562 Days)
Parity	10 : 1
Emission price	7.99 €
Emission volume	N/A
Settlement	règlement en espèces
Currency	EUR

Technical Indicators

Highest since issue	10.94 €
Lowest since issue	5.86 €
Delta	-0.41x
Omega	2.761
Premium	7.98x
Gearing	6.72x
Moneyness	1.069
Difference Strike	31.29 $
Difference Strike %	+6.26%
Spread	0.15 €
Spread %	2.30%
Theoretical value	6.420
Implied Volatility	31.78 %
Total Loss Probability	43.70 %
Intrinsic value	2.824
Present value	3.596
Break even	430.67 €
Theta	-0.02x
Vega	0.21x
Rho	-0.37x

Company Profile

Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases. Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).

Sector

More about the company

Ratings for Vertex Pharmaceuticals Incorporated

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Consensus: Vertex Pharmaceuticals Incorporated

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

473.8 USD

Average target price

468.3 USD

Spread / Average Target

-1.16%

Consensus